← Leaderboards
Jana Van De Goor
Onl Therapeutics, Inc.
$1,219,466
Attributed
$1,219,466
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $719.7K · FY2017–18$1M$750K$500K$250K$0
'17
'18
Funding mix
By agency
NIH$1,219,466 · 1
By mechanism
SB1$1,219,466 · 1
Top collaborators
No co-investigators on record.
Most similar at Onl Therapeutics, Inc.
Same institution · by research overlap
- Andrew Joseph Kocab$699,528
- Linda Lea Johnson$1,408,246
- Jeffrey A Jamison$421,640
Others in their field
Other Emerging Leaders on “Acute”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$51,003,204
- Julie Ake · National Institute Of Allergy And Infectious Diseases$41,692,120
- Xinhua Li · Nano Terra, Inc.$29,991,620
- Wendy Sammons-Jackson · National Institute Of Allergy And Infectious Diseases$29,269,420
- Evan Z Macosko · Broad Institute, Inc.$27,107,011
Research focus
AcuteAge Related Macular DegenerationAffectAnimal ModelApplications GrantsAwardBackAnatomyBiological SciencesBiotechnologyBlindnessCapitalCd95 AntigensCell DeathCell PhysiologyCellsCell SurvivalCessation Of LifeChronicChronic DiseaseClinical DevelopmentClinical TrialsCommercial ApplicationCommercialization
Grant awards (3)
De-risking ONL1204 to enable venture capital investment for first-in-human clinical trials$499,844
SB1 · FY2018 · EY · contact PI
De-risking ONL1204 to enable venture capital investment for first-in-human clinical trials$219,861
SB1 · FY2018 · EY · contact PI
De-risking ONL1204 to enable venture capital investment for first-in-human clinical trials$499,761
SB1 · FY2017 · EY · contact PI